Michael Van Werden has over 15 years of experience in clinical research as a Clinical Research Associate and Senior Clinical Research Associate. He has conducted monitoring visits and reviewed clinical data for trials across various therapeutic areas including endocrinology, neurology, dermatology, infectious diseases, and rheumatology. His responsibilities included training other staff, resolving data queries with study sites, and preparing project management reports. He holds a Bachelor of Sciences degree in Dietetics from Iowa State University with minors in Business and Spanish.
Part of the MaRS BioEntrepreneurship event series
Speaker: Wendy Hill, Gap Strategies
This event is available as an audio file:
http://www.marsdd.com/bioent/feb12
This slideshow was created by April Finnen of Dynport Vaccine Company LLC of Frederick, Maryland and was shared with me for the purposes of my column on Examiner.com.
Coronado Biosciences is engaged in the development of novel immunotherapy biologic agents. The Company's two principal pharmaceutical product candidates in clinical development are: CNDO-201, a biologic for the treatment of autoimmune diseases, such as Crohn's disease, ulcerative colitis and multiple sclerosis; and CNDO-109, a biologic that activates natural killer cells, for the treatment of acute myeloid leukemia and solid tumors.
The Company recently completed a $25.8 million round of financing and is using the proceeds to advance its pipeline, including funding Phase II double-blind, placebo controlled trial of CNDO-201 for the treatment of Crohn's Disease scheduled for initiation in early 2012 and a Phase I/II dose escalation and expansion trial of CNDO-109 for the treatment of relapsed Acute Myeloid Leukemia (AML) planned for 2012. Each of these drugs is a novel therapy that has achieved clinical proof-of-concept in indications with unmet medical needs.
Early phase drug development and the fda roadmap final version 2axE. Dennis Bashaw
This is the slide deck used in my webinar that was presented on 2/1/2018 on the FDA Predictive Toxicology Roadmap. It was presented at a webinar hosted by BioIVT in my private capacity and is not an official statement of FDA policy
Professor Matthias von Herrath MD, Vice President and Head Diabetes R&D Center, Novo Nordisk Inc, Seattle, Washington USA. http://www.garvan.org.au/news-events/leaders-in-science-and-society
Part of the MaRS BioEntrepreneurship event series
Speaker: Wendy Hill, Gap Strategies
This event is available as an audio file:
http://www.marsdd.com/bioent/feb12
This slideshow was created by April Finnen of Dynport Vaccine Company LLC of Frederick, Maryland and was shared with me for the purposes of my column on Examiner.com.
Coronado Biosciences is engaged in the development of novel immunotherapy biologic agents. The Company's two principal pharmaceutical product candidates in clinical development are: CNDO-201, a biologic for the treatment of autoimmune diseases, such as Crohn's disease, ulcerative colitis and multiple sclerosis; and CNDO-109, a biologic that activates natural killer cells, for the treatment of acute myeloid leukemia and solid tumors.
The Company recently completed a $25.8 million round of financing and is using the proceeds to advance its pipeline, including funding Phase II double-blind, placebo controlled trial of CNDO-201 for the treatment of Crohn's Disease scheduled for initiation in early 2012 and a Phase I/II dose escalation and expansion trial of CNDO-109 for the treatment of relapsed Acute Myeloid Leukemia (AML) planned for 2012. Each of these drugs is a novel therapy that has achieved clinical proof-of-concept in indications with unmet medical needs.
Early phase drug development and the fda roadmap final version 2axE. Dennis Bashaw
This is the slide deck used in my webinar that was presented on 2/1/2018 on the FDA Predictive Toxicology Roadmap. It was presented at a webinar hosted by BioIVT in my private capacity and is not an official statement of FDA policy
Professor Matthias von Herrath MD, Vice President and Head Diabetes R&D Center, Novo Nordisk Inc, Seattle, Washington USA. http://www.garvan.org.au/news-events/leaders-in-science-and-society
1. Michael Van Werden
San Diego, CA 92116
619-890-9873
e-mail: dockersii@yahoo.com
Professional Experience
Quintiles, San Diego, CA (1/2012 – 7/2016)
Sr. Clinical Research Associate III
Conduct Monitoring and review (site selection, initiation, routine/interim, and close-
out visits) at investigator sites following FDA regulatory requirements (Good Clinical
Practices / ICH-GCP; 21 Code of Federal Regulations, ALCOA principles)
Participate in site recruitment, selection and initiation activities for clinical trials
Train junior CRAs on monitoring, internal procedures, and query resolution
Additional tasks (as listed for previous CRA job)
Project Experience
III Endocrine / Diabetes / Biosimilar insulin for Type 1 diabetics
III Neurology / Diabetic Neuropathy
III Endocrine / Diabetes / Biosimilar insulin for Type 2 diabetics
III Endocrine / Diabetes / Type 2 diabetic oral medication
III Dermatology / Psoriasis / Biosimilar biologic treatment (injection)
PharmaNet, San Diego, CA
Clinical Research Associate II (02/2007 – 12/2011)
Clinical Research Associate I (05/2005 – 01/2007)
Conduct Monitoring Visits (SSV, SIV, RMV/IMV, COV)
Participate in site recruitment, selection and initiation activities for clinical trials
Experience conducting eCRF review with various types of Electronic Data Capture
(EDC – InForm, RAVE, etc.); experience with IVRS & IWRS systems
Review and verify CRFs and other clinical data for completeness, integrity and
accuracy; generate queries
Maintain patient tracking records for multiple sites
Train site staff
Resolve queries of CRF data with study site personnel
Prepare and process Serious Adverse Event (SAE) reports
Prepare project management reports for clients, project personnel, and internal
management
Review of Informed Consents (ICFs)
Assistance in development of source documents
Experience with multiple Central/local labs; Central IRBs and Quality of Life surveys
Manage time well and follow through on pending issues/action items until completion
2. Michael Van Werden Page 2
Project Experience
Phase Therapeutic area, Sub Indication and Drug Class
I/II Endocrine / X-Linked Hypophosphatemia (human monoclonal antibody)
II Endocrine / Oral Testosterone Undecanoate (TU) in Hypogonadal Men
II Coronary / carotid stenosis
II Infectious disease / West Nile Virus / immunizations / vaccine
II Nervous / chronic lower back pain / TNF-α inhibitor
III Rheumatology / rheumatoid arthritis / IL-6 inhibitor
II Infectious disease / vaccine for meningitis/ immunizations / vaccine
III Infectious disease / vaccine for meningitis/ immunizations / vaccine
IV Infectious disease / HIV
II Urology / erectile dysfunction / α-MSH analog
III Neurology / Parkinson’s Disease
BioPhase Solutions, San Diego, CA 02/2005 – 05/2005
Contracted to Structural GenomiX, San Diego, CA
Clinical Trial Assistant
Therapeutic areas – acute myeloid leukemia / solid tumors
Prepared and sent regulatory packets including confidentiality agreements, protocol
synopsis, clinical study agreements, clinical trial agreements, Investigator’s
brochure, Feasibility Questionnaires and study budgets to Investigators
Reviewed clinical documents for a newly in-licensed cancer drug in Phases I/II and
created a new filing system for them at Structural GenomiX
Education
Iowa State University, Ames, IA
(+2 courses: Human Pharmacology)
Bachelor of Sciences – Dietetics
Double Minor- Business, Spanish
Professional Memberships / Certifications
Professional Certification in Clinical Trials Management & Administration, University of
California, San Diego, CA, 2003
Biostator certification
Languages
English (fluent)
Spanish (fluent)